Correction to: Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic

Brandon Brown; Jamie L Weiss; Scott Kolodny; Xiangyi Meng; Ian M Williams; John A Osborne

doi:10.1186/s12883-019-1568-z

Correction to: Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic

BMC Neurol. 2019 Dec 21;19(1):336. doi: 10.1186/s12883-019-1568-z.

Authors

Brandon Brown¹, Jamie L Weiss¹, Scott Kolodny¹, Xiangyi Meng¹, Ian M Williams², John A Osborne³

Affiliations

¹ Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA.
² Oxford PharmaGenesis, Tubney Warren Barn, Tubney, Oxford, OX13 5QJ, UK.
³ State of the Heart Cardiology, Plaza 1, Medical Pkwy. N Suite 103, Dallas, TX, 75234, USA. josborne@sothcardiology.com.

Abstract

Following publication of the original article [1], the authors reported a mistake regarding the year found in the paragraph of the Background section.

Publication types

Published Erratum